Dual antiplatelet therapy is associated with high α-tubulin acetylation in circulating platelets from coronary artery disease patients
In conclusion, our study highlights the role of elevated platelet α-tubulin K40 acetylation as a marker of platelet inhibition in response to DAPT.Clinical trial registration: https://clinicaltrials.gov - NCT03034148.PMID:37700239 | DOI:10.1080/09537104.2023.2250002
Source: Platelets - Category: Hematology Authors: Valentine Robaux Shakeel Kautbally Audrey Ginion M élanie Dechamps Sibille Lejeune Nassiba Menghoum Luc Bertrand Anne-Catherine Pouleur Sandrine Horman Christophe Beauloye Source Type: research
More News: Angiography | Angioplasty | Aspirin | Clinical Trials | Coronary Angioplasty | Hematology | Men | Percutaneous Coronary Intervention | Study